{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:43:51Z","timestamp":1771332231030,"version":"3.50.1"},"reference-count":29,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1F1A1050281"],"award-info":[{"award-number":["NRF-2021R1F1A1050281"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The price of cancer drugs has skyrocketed, yet it is not clear whether their value is commensurate with their price. More cancer drugs are approved under expedited review, which considers less rigorous clinical evidence, yet only 20% of them show an overall survival gain in the confirmatory trial. Moreover, clinical data are often generated based on small, single-arm studies with surrogate outcomes, challenging economic evaluation. With their high price and uncertain (marginal) clinical value, cancer drugs are frequently rejected by health technology assessment (HTA) bodies. Therefore, agencies, including the UK\u2019s National Institute for Health and Care Excellence (NICE), have adopted cancer drug funds (CDF) or risk-sharing schemes to provide extra access for expensive cancer drugs which fail to meet NICE\u2019s cost effectiveness threshold. With rising pricing and fewer new cancer medications with novel mechanisms of action, it is unclear if newly marketed cancer therapies address unmet clinical needs or whether we are paying too much. Transparency, equity, innovativeness, and sustainability are all harmed by a \u201cspecial\u201d approach for cancer medications. If early access is allowed, confirmatory trials within a certain time frame and economic evaluation should be conducted, and label changes or disinvestment should be carried out based on those evaluations.<\/jats:p>","DOI":"10.3390\/ijerph19074204","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:22:39Z","timestamp":1648848159000},"page":"4204","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8048-0670","authenticated-orcid":false,"given":"Gyeongseon","family":"Shin","sequence":"first","affiliation":[{"name":"College of Pharmacy, Ewha Womans University, Seoul 03760, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Young","family":"Kwon","sequence":"additional","affiliation":[{"name":"Division of Biology and Public Health, Mokwon University, Deajeon 35349, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-8884","authenticated-orcid":false,"given":"SeungJin","family":"Bae","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Ewha Womans University, Seoul 03760, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"ref_1","unstructured":"IQVIA (2021, December 30). Global Oncology Trends. Available online: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/global-oncology-trends-2021."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamainternmed.2020.5921","article-title":"Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018","volume":"181","author":"DeMartino","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Richard, P., Patel, N., Lu, Y.-C., Walker, R., and Younis, M. (2021). The Financial Burden of Cancer on Families in the United States. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18073790"},{"key":"ref_4","first-page":"321","article-title":"Can we achieve affordable cancer medicine prices? Developing a pathway for change","volume":"21","author":"Vogler","year":"2021","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gandjour, A. (2021). The price of curing cancer. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-07327-x"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40258-021-00670-4","article-title":"Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America","volume":"20","author":"Vogler","year":"2022","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1108\/JHOM-08-2020-0344","article-title":"Consumer perspectives of accelerated access to medicines: A qualitative study","volume":"35","author":"Pace","year":"2021","journal-title":"J. Health Organ. Manag."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","article-title":"Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated with New Cancer Medicines","volume":"3","author":"Iliopoulos","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113042","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","volume":"258","author":"Shearer","year":"2020","journal-title":"Soc. Sci. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1200\/JOP.17.00058","article-title":"Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time","volume":"14","author":"Saluja","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","article-title":"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000\u20132015","volume":"28","author":"Vivot","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: A cost\u2013benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/blr.2015.9999","article-title":"FDA\u2019s expedited approval mechanisms for new drug products","volume":"34","author":"Kepplinger","year":"2015","journal-title":"Biotechnol. Law Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA Approval and Regulation of Pharmaceuticals, 1983\u20132018","volume":"323","author":"Darrow","year":"2020","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009\u201313","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended Consequences of Expensive Cancer Therapeutics\u2014The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol.\u2013Head Neck Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"h4633","DOI":"10.1136\/bmj.h4633","article-title":"Trends in utilization of FDA expedited drug development and approval programs, 1987\u20132014: Cohort study","volume":"351","author":"Kesselheim","year":"2015","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration","volume":"318","author":"Naci","year":"2017","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_21","unstructured":"FDA (2022, March 21). Withdrawn | Cancer Accelerated Approvals, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n1959","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: Retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"n2191","DOI":"10.1136\/bmj.n2191","article-title":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment","volume":"374","author":"Dawoud","year":"2021","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Morrell, L., Wordsworth, S., Schuh, A., Middleton, M.R., Rees, S., and Barker, R.W. (2018). Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. BMC Health Serv. Res., 18.","DOI":"10.1186\/s12913-018-3162-2"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/annonc\/mdx110","article-title":"Do patient access schemes for high-cost cancer drugs deliver value to society?\u2014lessons from the NHS Cancer Drugs Fund","volume":"28","author":"Aggarwal","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jval.2016.04.001","article-title":"Did It Matter That the Cancer Drugs Fund Was Not NICE? A Retrospective Review","volume":"19","author":"Dixon","year":"2016","journal-title":"Value Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"h2068","DOI":"10.1136\/bmj.h2068","article-title":"Why do cancer drugs get such an easy ride?","volume":"350","author":"Light","year":"2015","journal-title":"BMJ"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2138793","DOI":"10.1001\/jamanetworkopen.2021.38793","article-title":"Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action","volume":"4","author":"Olivier","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.mayocp.2016.04.028","article-title":"The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable","volume":"91","author":"Prasad","year":"2016","journal-title":"Mayo Clin. Proc."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/7\/4204\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:48:14Z","timestamp":1760136494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/7\/4204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijerph19074204"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19074204","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}